Corbus Pharmaceuticals Holdings, Inc. Interest Income (Expense), Nonoperating, Net
Corbus Pharmaceuticals Holdings, Inc. (CRBP) reported Interest Income (Expense), Nonoperating, Net of $292.85 thousand for the 3-month period ending 2019-09-30, per its 10-Q filed 2019-11-07.
Discontinued › Income Statement › Other Income
us-gaap:InterestIncomeExpenseNonoperatingNet · last filed 2019-11-07
- Corbus Pharmaceuticals Holdings, Inc. interest income (expense), nonoperating, net for the quarter ending 2019-09-30 was $292.85K, a 9.14% increase year-over-year.
- Corbus Pharmaceuticals Holdings, Inc. interest income (expense), nonoperating, net for the quarter ending 2019-06-30 was $448.72K, a 68.50% increase year-over-year.
- Corbus Pharmaceuticals Holdings, Inc. interest income (expense), nonoperating, net for the quarter ending 2019-03-31 was $334.60K, a 64.48% increase year-over-year.
- Corbus Pharmaceuticals Holdings, Inc. interest income (expense), nonoperating, net for the quarter ending 2018-12-31 was $244.72K, a 83.90% increase year-over-year.
- Corbus Pharmaceuticals Holdings, Inc. interest income (expense), nonoperating, net for fiscal 2018 was $982.78K, a 436.71% increase from fiscal 2017.
- Corbus Pharmaceuticals Holdings, Inc. interest income (expense), nonoperating, net for fiscal 2017 was $183.11K, a 38288.26% increase from fiscal 2016.
- Corbus Pharmaceuticals Holdings, Inc. interest income (expense), nonoperating, net for fiscal 2016 was $477.00, a 51.18% decline from fiscal 2015.
- Corbus Pharmaceuticals Holdings, Inc. interest income (expense), nonoperating, net for fiscal 2015 was $977.00.
| Period end | Interest Income (Expense), Nonoperating, Net 3 month | Interest Income (Expense), Nonoperating, Net 6 month | Interest Income (Expense), Nonoperating, Net 9 month | Interest Income (Expense), Nonoperating, Net 12 month |
|---|---|---|---|---|
| 2019-09-30 | $292.85K 10-Q · filed 2019-11-07 | $741.57K derived: sum of 2 quarters · filed 2019-11-07 | $1.08M 10-Q · filed 2019-11-07 | $1.32M derived: sum of 4 quarters · filed 2019-11-07 |
| 2019-06-30 | $448.72K 10-Q · filed 2019-08-08 | $783.31K 10-Q · filed 2019-08-08 | $1.03M derived: sum of 3 quarters · filed 2019-08-08 | $1.30M derived: sum of 4 quarters · filed 2019-11-07 |
| 2019-03-31 | $334.60K 10-Q · filed 2019-05-09 | $579.32K derived: sum of 2 quarters · filed 2019-05-09 | $847.65K derived: sum of 3 quarters · filed 2019-11-07 | $1.11M derived: sum of 4 quarters · filed 2019-11-07 |
| 2018-12-31 | $244.72K derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-12 | $513.06K derived: sum of 2 quarters · filed 2019-11-07 | $779.36K derived: sum of 3 quarters · filed 2019-11-07 | $982.78K 10-K · filed 2019-03-12 |
| 2018-09-30 | $268.33K 10-Q · filed 2019-11-07 | $534.63K derived: sum of 2 quarters · filed 2019-11-07 | $738.05K 10-Q · filed 2019-11-07 | $871.13K derived: sum of 4 quarters · filed 2019-11-07 |
| 2018-06-30 | $266.30K 10-Q · filed 2019-08-08 | $469.72K 10-Q · filed 2019-08-08 | $602.79K derived: sum of 3 quarters · filed 2019-08-08 | $646.19K derived: sum of 4 quarters · filed 2019-08-08 |
| 2018-03-31 | $203.42K 10-Q · filed 2019-05-09 | $336.49K derived: sum of 2 quarters · filed 2019-05-09 | $379.90K derived: sum of 3 quarters · filed 2019-05-09 | $385.17K derived: sum of 4 quarters · filed 2019-05-09 |
| 2017-12-31 | $133.07K 10-K · filed 2018-03-12 | $176.47K derived: sum of 2 quarters · filed 2018-11-08 | $181.75K derived: sum of 3 quarters · filed 2018-11-08 | $183.11K 10-K · filed 2019-03-12 |
| 2017-09-30 | $43.40K 10-Q · filed 2018-11-08 | $48.67K derived: sum of 2 quarters · filed 2018-11-08 | $50.04K 10-Q · filed 2018-11-08 | $50.10K derived: sum of 4 quarters · filed 2018-11-08 |
| 2017-06-30 | $5.27K 10-Q · filed 2018-08-08 | $6.64K 10-Q · filed 2018-08-08 | $6.69K derived: sum of 3 quarters · filed 2018-08-08 | $8.43K derived: sum of 4 quarters · filed 2018-08-08 |
| 2017-03-31 | $1.37K 10-K · filed 2018-03-12 | $1.42K derived: sum of 2 quarters · filed 2018-05-10 | $3.15K derived: sum of 3 quarters · filed 2018-05-10 | $7.20K derived: sum of 4 quarters · filed 2018-05-10 |
| 2016-12-31 | $57.00 10-K · filed 2018-03-12 | $1.79K derived: sum of 2 quarters · filed 2018-03-12 | $5.84K derived: sum of 3 quarters · filed 2018-03-12 | $477.00 10-K · filed 2018-03-12 |
| 2016-09-30 | $1.73K 10-K · filed 2018-03-12 | $5.78K derived: sum of 2 quarters · filed 2018-03-12 | $420.00 10-Q · filed 2017-11-08 | $624.00 derived: sum of 4 quarters · filed 2018-03-12 |
| 2016-06-30 | $4.05K 10-K · filed 2018-03-12 | -$1.31K 10-Q · filed 2017-08-09 | -$1.11K derived: sum of 3 quarters · filed 2018-03-12 | -$70.00 derived: sum of 4 quarters · filed 2018-03-12 |
| 2016-03-31 | -$5.36K 10-K · filed 2018-03-12 | -$5.16K derived: sum of 2 quarters · filed 2018-03-12 | -$4.12K derived: sum of 3 quarters · filed 2018-03-12 | -$3.96K derived: sum of 4 quarters · filed 2018-03-12 |
| 2015-12-31 | $204.00 derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-12 | $1.24K derived: sum of 2 quarters · filed 2018-03-12 | $1.40K derived: sum of 3 quarters · filed 2018-03-12 | $977.00 10-K · filed 2018-03-12 |
| 2015-09-30 | $1.04K 10-Q · filed 2016-11-10 | $1.19K derived: sum of 2 quarters · filed 2016-11-10 | $773.00 10-Q · filed 2016-11-10 | |
| 2015-06-30 | $155.00 10-Q · filed 2016-08-12 | -$264.00 10-Q · filed 2016-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |